Triple Negative Breast Cancer — Cisplatin vs Paclitaxel for Triple Negative Breast Cancer
Citation(s)
A Randomized Phase II Study of Preoperative Cisplatin Versus Paclitaxel in Patients With Triple Negative Breast Cancer: Evaluating the Homologous Recombination Deficiency (HRD) Biomarker